系统性硬化症相关间质性肺病进展不同定义的一致性与预后价值
本研究纳入245例系统性硬化症相关间质性肺病(SSc-ILD)患者,评估四种进展定义在24个月内的判定一致性及对60个月疾病相关死亡风险的预后价值。结果显示不同定义不可互换,最多三分之一病例分类不同,且预后价值在特定临床亚组中存在差异。
要点
- 四种进展定义对SSc-ILD进展的判定不一致,最多三分之一病例分类不同。
- FVC最小临床重要恶化、OMERACT和Erice定义与死亡率相关,EUSTAR定义未显示关联。
- 在病程≥3年、轻度功能损害或肺动脉收缩压≥40 mm Hg患者中,进展与死亡关联较弱。
核心结论
- 四种SSc-ILD进展定义不可互换,导致最多三分之一病例分类不同,且预后价值在特定临床亚组中存在差异。
研究设计与样本
- 对245例连续SSc-ILD患者评估24个月内进展状态,并比较进展者与非进展者的60个月疾病相关死亡风险。
主要发现
- 245例患者中报告26例SSc相关死亡。
- FVC最小临床重要恶化定义与死亡率相关(HR 2.27;95%CI 1.03-4.97)。
- OMERACT定义与死亡率相关(HR 2.90;95%CI 1.28-6.57)。
- Erice定义与死亡率相关(HR 2.69;95%CI 1.23-5.89)。
- 在病程≥3年、轻度功能损害和肺动脉收缩压≥40 mm Hg患者中,进展与死亡关联较差。
关键数值与推荐
- Erice标准在病程≥3年、局限皮肤型及肺动脉收缩压<40 mm Hg患者中表现更优。
- OMERACT标准在弥漫皮肤型伴严重功能损害患者中表现更好。
临床怎么用
- 临床解读SSc-ILD进展时应明确所用定义,不同定义不可互换。
- 在特定临床亚组(如长病程、轻度功能损害、肺动脉高压)中需谨慎解读进展定义的预后价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Interstitial lung disease (ILD) in systemic sclerosis (SSc) is a common complication that has a varied progression rate and prognosis. Different progression definitions are available, including minimal clinically important worsening of FVC, EUSTAR (European Scleroderma Trials and Research Group) progression, OMERACT (Outcome Measures in Rheumatology Clinical Trials) progression, and Erice ILD working group progression. Pulmonary function and symptom changes may act as specific confounding factors when applying these definitions in SSc. Objectives: To assess the concordance and prognostic value of four different definitions in patients with SSc-ILD overall and in specific clinical groups. Methods: Progression status in consecutive patients with SSc-ILD was assessed over 24 months, and 60-month disease-related mortality risk was compared between progressors and nonprogressors using four definitions. Measurements and Main Results: Among 245 patients, 26 SSc-related deaths were reported. Mortality was linked to progression for minimal clinically important worsening of FVC (hazard ratio [HR], 2.27; 95% confidence interval [CI], 1.03-4.97), OMERACT (HR, 2.90; 95% CI, 1.28-6.57), and Erice definitions (HR, 2.69; 95% CI, 1.23-5.89). The association between progression and mortality was poor in patients with disease duration ≥3 years, mild functional impairment, and pulmonary artery systolic pressure ≥40 mm Hg. Erice criteria appeared superior in patients with duration ≥3 years, limited cutaneous variant, and pulmonary artery systolic pressure <40 mm Hg. OMERACT criteria performed better in diffuse cutaneous variant patients with severe functional impairment. Conclusions: The four evaluated definitions of progression in SSc-ILD are not interchangeable, resulting in up to one-third of cases being classified differently on the basis of adopted criteria and presenting different prognostic values, particularly within specific clinical groups.
引用
- De Lorenzis E, Del Galdo F, Natalello G, et al. Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression. Am J Respir Crit Care Med. 2024. PMID: 39078207. doi:10.1164/rccm.202311-2153OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。